SHEN Rui,XU Jing,WANG Lei,et al.Ganoderma lucidum Polysaccharides Inhibit Malignant Phenotype of Hepatocellular Carcinoma Cells by Regulating PI3K/Akt Signaling Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(06):88-94.
polysaccharides (GLP) on the proliferation, migration, cycle, and apoptosis of hepatocellular carcinoma SKHEP1 and Huh7 cells and to explore the underlying mechanism.
Method
2
SK-HEP-1 and Huh-7 cells were classified into the blank group and low-, medium-, and high-dose GLP groups (3.5, 7, 14 g·L
-1
). The proliferation of the cells was examined by cell counting kit-8 (CCK8) assay, and the migration by scratch assay. Cell cycle was measured by flow cytometry and apoptosis was detected based on Hoechst33258 staining. In addition, the expression of phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt), phosphorylated PI3K (pPI3K), and phosphorylated Akt (pAkt) in the cells was determined by Western blot.
Result
2
Compared with the blank group, the three doses of GLP reduced the proliferation and migration of SKHEP1 and Huh7 cells (
P
<
0.05), increased the percentage of cells in G
1
phase (
P
<
0.05), and decreased percentage of cells in S and G
2
phase (
P
<
0.05). In addition, the three doses can induce apoptosis of both SK-HEP-1 and Huh-7 cells, particularly the high dose. Moreover, the three doses of GLP lowered the levels of pPI3K and pAkt (
P
<
0.05).
Conclusion
2
GLP significantly inhibited the malignant phenotype of SK-HEP-1 and Huh-7 cells through the PI3K/Akt signaling pathway.
YANG J D, HEIMBACH J K. New advances in the diagnosis and management of hepatocellular carcinoma[J]. BMJ, 2020, doi: 10.1136/bmj.m3544http://dx.doi.org/10.1136/bmj.m3544.
TANG W, CHEN Z, ZHANG W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: Theoretical basis and therapeutic aspects[J]. Signal Transduct Target Ther, 2020, 5(1):87.
HATANAKA T, NAGANUMA A, KAKIZAKI S. Lenvatinib for hepatocellular carcinoma: A literature review[J]. Pharmaceuticals (Basel), 2021, 14(1):36.
ANWANWAN D, SINGH SK, SINGH S, et al. Challenges in liver cancer and possible treatment approaches[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(1):188314.
JUAID N, AMIN A, ABDALLA A, et al. Anti-hepatocellular carcinoma biomolecules: Molecular targets insights[J]. Int J Mol Sci, 2021, 22(19):10774.
LIU G,ZENG T. Sporoderm-removed Ganoderma lucidum spore powder may suppress the proliferation, migration, and invasion of esophageal squamous cell carcinoma cells through PI3K/Akt/mTOR and ERK pathway[J].Integr Cancer Ther,2021,20:15347354211062157.
GUO C,GUO D,FANG L,et al.Ganoderma lucidum polysaccharide modulates gut microbiota and immune cell function to inhibit inflammation and tumorigenesis in colon[J].Carbohydr Polym,2021,267:118231.
SONG M,LI Z H,GU H S,et al.Ganoderma lucidum spore polysaccharide inhibits the growth of hepatocellular carcinoma cells by altering macrophage polarity and induction of apoptosis[J].J Immunol Res,2021,2021:6696606.
HSU W H, QIU W L, TSAO S M, et al. Effects of WSG, a polysaccharide from Ganoderma lucidum, on suppressing cell growth and mobility of lung cancer[J]. Int J Biol Macromol, 2020, 165(Pt A):1604-1613.
FRESNO VARA J A, CASADO E, DE CASTRO J, et al. PI3K/Akt signalling pathway and cancer[J]. Cancer Treat Rev, 2004, 30(2):193-204.
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
SEWERYN E, ZIALA A, GAMIAN A. Health-promoting of polysaccharides extracted from Ganoderma lucidum[J]. Nutrients, 2021, 13(8):2725.
FU Y,SHI L,DING K.Structure elucidation and anti-tumor activity in vivo of a polysaccharide from spores of Ganoderma lucidum (Fr.) Karst[J].Int J Biol Macromol,2019,141:693-699.
LIU Y J,SHEN J,XIA Y M,et al.The polysaccharides from Ganoderma lucidum: Are they always inhibitors on human hepatocarcinoma cells?[J].Carbohydr Polym,2012,90(3):1210-1215.
HUANG D H, JIAN J, LI S, et al. TPX2 silencing exerts anti‑tumor effects on hepatocellular carcinoma by regulating the PI3K/Akt signaling pathway[J]. Int J Mol Med, 2019, 44(6):2113-2122.